Global Pet Inactivated Vaccine Market Growth 2025-2031

Publication ID:

LPI03258624

Publication Date:

March 5, 2025

Pages:

Publisher:

LPI

Countries:

Global [1]

USD 3,660.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

The global Pet Inactivated Vaccine market size is predicted to grow from US$ 554 million in 2025 to US$ 777 million in 2031; it is expected to grow at a CAGR of 5.8% from 2025 to 2031.
Inactivated vaccines for pets are vaccines made from killed pathogens.
According to Our PET Supplies Research Center, the global pet industry reached $ 261 billion in 2022, a year-on-year increase of 11.3%. The United States gains the highest pet penetration rate and becomes the largest pet market. According to the American Pet Products Association (APPA), 66% of American households keep pets, and the total industry sales was about US$136.8 billion, an increase of 10.8% over 2021. According to IVH, the German pet products industry association, the number of pets in Germany reached 33.4 million in 2022, with a total turnover of nearly 鈧�6.5 billion. The 2023 China Pet Industry Trend Insight White Paper released by JD shows that the market size of the four major pet physical commodities is increasing year by year: pet supplies account for 45%, pet staple food accounts for nearly 35%, pet snacks account for 12%, and pet medicine and health care account for 377%.
The 鈥淧et Inactivated Vaccine Industry Forecast鈥� looks at past sales and reviews total world Pet Inactivated Vaccine sales in 2024, providing a comprehensive analysis by region and market sector of projected Pet Inactivated Vaccine sales for 2025 through 2031. With Pet Inactivated Vaccine sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Pet Inactivated Vaccine industry.
This Insight Report provides a comprehensive analysis of the global Pet Inactivated Vaccine landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Pet Inactivated Vaccine portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms鈥� unique position in an accelerating global Pet Inactivated Vaccine market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Pet Inactivated Vaccine and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Pet Inactivated Vaccine.
This report presents a comprehensive overview, market shares, and growth opportunities of Pet Inactivated Vaccine market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
Obtained by Heat Killing
Killed by Chemical Methods such as Formaldehyde
Obtained by Radiation Killing
Segmentation by Application:
Dog
Cat
Dird
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
Bayer Healthcare
Vetoquinol S.A
Boehringer Ingelheim
Ceva
Eli Lilly
Heska
Merck Animal Health
Merial (Sanofi)
Virbac
Pfizer
Key Questions Addressed in this Report
What is the 10-year outlook for the global Pet Inactivated Vaccine market?
What factors are driving Pet Inactivated Vaccine market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Pet Inactivated Vaccine market opportunities vary by end market size?
How does Pet Inactivated Vaccine break out by Type, by Application?

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Pet Inactivated Vaccine Annual Sales 2020-2031
2.1.2 World Current & Future Analysis for Pet Inactivated Vaccine by Geographic Region, 2020, 2024 & 2031
2.1.3 World Current & Future Analysis for Pet Inactivated Vaccine by Country/Region, 2020, 2024 & 2031
2.2 Pet Inactivated Vaccine Segment by Type
2.2.1 Obtained by Heat Killing
2.2.2 Killed by Chemical Methods such as Formaldehyde
2.2.3 Obtained by Radiation Killing
2.3 Pet Inactivated Vaccine Sales by Type
2.3.1 Global Pet Inactivated Vaccine Sales Market Share by Type (2020-2025)
2.3.2 Global Pet Inactivated Vaccine Revenue and Market Share by Type (2020-2025)
2.3.3 Global Pet Inactivated Vaccine Sale Price by Type (2020-2025)
2.4 Pet Inactivated Vaccine Segment by Application
2.4.1 Dog
2.4.2 Cat
2.4.3 Dird
2.4.4 Others
2.5 Pet Inactivated Vaccine Sales by Application
2.5.1 Global Pet Inactivated Vaccine Sale Market Share by Application (2020-2025)
2.5.2 Global Pet Inactivated Vaccine Revenue and Market Share by Application (2020-2025)
2.5.3 Global Pet Inactivated Vaccine Sale Price by Application (2020-2025)
3 Global by Company
3.1 Global Pet Inactivated Vaccine Breakdown Data by Company
3.1.1 Global Pet Inactivated Vaccine Annual Sales by Company (2020-2025)
3.1.2 Global Pet Inactivated Vaccine Sales Market Share by Company (2020-2025)
3.2 Global Pet Inactivated Vaccine Annual Revenue by Company (2020-2025)
3.2.1 Global Pet Inactivated Vaccine Revenue by Company (2020-2025)
3.2.2 Global Pet Inactivated Vaccine Revenue Market Share by Company (2020-2025)
3.3 Global Pet Inactivated Vaccine Sale Price by Company
3.4 Key Manufacturers Pet Inactivated Vaccine Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Pet Inactivated Vaccine Product Location Distribution
3.4.2 Players Pet Inactivated Vaccine Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 World Historic Review for Pet Inactivated Vaccine by Geographic Region
4.1 World Historic Pet Inactivated Vaccine Market Size by Geographic Region (2020-2025)
4.1.1 Global Pet Inactivated Vaccine Annual Sales by Geographic Region (2020-2025)
4.1.2 Global Pet Inactivated Vaccine Annual Revenue by Geographic Region (2020-2025)
4.2 World Historic Pet Inactivated Vaccine Market Size by Country/Region (2020-2025)
4.2.1 Global Pet Inactivated Vaccine Annual Sales by Country/Region (2020-2025)
4.2.2 Global Pet Inactivated Vaccine Annual Revenue by Country/Region (2020-2025)
4.3 Americas Pet Inactivated Vaccine Sales Growth
4.4 APAC Pet Inactivated Vaccine Sales Growth
4.5 Europe Pet Inactivated Vaccine Sales Growth
4.6 Middle East & Africa Pet Inactivated Vaccine Sales Growth
5 Americas
5.1 Americas Pet Inactivated Vaccine Sales by Country
5.1.1 Americas Pet Inactivated Vaccine Sales by Country (2020-2025)
5.1.2 Americas Pet Inactivated Vaccine Revenue by Country (2020-2025)
5.2 Americas Pet Inactivated Vaccine Sales by Type (2020-2025)
5.3 Americas Pet Inactivated Vaccine Sales by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Pet Inactivated Vaccine Sales by Region
6.1.1 APAC Pet Inactivated Vaccine Sales by Region (2020-2025)
6.1.2 APAC Pet Inactivated Vaccine Revenue by Region (2020-2025)
6.2 APAC Pet Inactivated Vaccine Sales by Type (2020-2025)
6.3 APAC Pet Inactivated Vaccine Sales by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Pet Inactivated Vaccine by Country
7.1.1 Europe Pet Inactivated Vaccine Sales by Country (2020-2025)
7.1.2 Europe Pet Inactivated Vaccine Revenue by Country (2020-2025)
7.2 Europe Pet Inactivated Vaccine Sales by Type (2020-2025)
7.3 Europe Pet Inactivated Vaccine Sales by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Pet Inactivated Vaccine by Country
8.1.1 Middle East & Africa Pet Inactivated Vaccine Sales by Country (2020-2025)
8.1.2 Middle East & Africa Pet Inactivated Vaccine Revenue by Country (2020-2025)
8.2 Middle East & Africa Pet Inactivated Vaccine Sales by Type (2020-2025)
8.3 Middle East & Africa Pet Inactivated Vaccine Sales by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Pet Inactivated Vaccine
10.3 Manufacturing Process Analysis of Pet Inactivated Vaccine
10.4 Industry Chain Structure of Pet Inactivated Vaccine
11 Marketing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Pet Inactivated Vaccine Distributors
11.3 Pet Inactivated Vaccine Customer
12 World Forecast Review for Pet Inactivated Vaccine by Geographic Region
12.1 Global Pet Inactivated Vaccine Market Size Forecast by Region
12.1.1 Global Pet Inactivated Vaccine Forecast by Region (2026-2031)
12.1.2 Global Pet Inactivated Vaccine Annual Revenue Forecast by Region (2026-2031)
12.2 Americas Forecast by Country (2026-2031)
12.3 APAC Forecast by Region (2026-2031)
12.4 Europe Forecast by Country (2026-2031)
12.5 Middle East & Africa Forecast by Country (2026-2031)
12.6 Global Pet Inactivated Vaccine Forecast by Type (2026-2031)
12.7 Global Pet Inactivated Vaccine Forecast by Application (2026-2031)
13 Key Players Analysis
13.1 Bayer Healthcare
13.1.1 Bayer Healthcare Company Information
13.1.2 Bayer Healthcare Pet Inactivated Vaccine Product Portfolios and Specifications
13.1.3 Bayer Healthcare Pet Inactivated Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
13.1.4 Bayer Healthcare Main Business Overview
13.1.5 Bayer Healthcare Latest Developments
13.2 Vetoquinol S.A
13.2.1 Vetoquinol S.A Company Information
13.2.2 Vetoquinol S.A Pet Inactivated Vaccine Product Portfolios and Specifications
13.2.3 Vetoquinol S.A Pet Inactivated Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
13.2.4 Vetoquinol S.A Main Business Overview
13.2.5 Vetoquinol S.A Latest Developments
13.3 Boehringer Ingelheim
13.3.1 Boehringer Ingelheim Company Information
13.3.2 Boehringer Ingelheim Pet Inactivated Vaccine Product Portfolios and Specifications
13.3.3 Boehringer Ingelheim Pet Inactivated Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
13.3.4 Boehringer Ingelheim Main Business Overview
13.3.5 Boehringer Ingelheim Latest Developments
13.4 Ceva
13.4.1 Ceva Company Information
13.4.2 Ceva Pet Inactivated Vaccine Product Portfolios and Specifications
13.4.3 Ceva Pet Inactivated Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
13.4.4 Ceva Main Business Overview
13.4.5 Ceva Latest Developments
13.5 Eli Lilly
13.5.1 Eli Lilly Company Information
13.5.2 Eli Lilly Pet Inactivated Vaccine Product Portfolios and Specifications
13.5.3 Eli Lilly Pet Inactivated Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
13.5.4 Eli Lilly Main Business Overview
13.5.5 Eli Lilly Latest Developments
13.6 Heska
13.6.1 Heska Company Information
13.6.2 Heska Pet Inactivated Vaccine Product Portfolios and Specifications
13.6.3 Heska Pet Inactivated Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
13.6.4 Heska Main Business Overview
13.6.5 Heska Latest Developments
13.7 Merck Animal Health
13.7.1 Merck Animal Health Company Information
13.7.2 Merck Animal Health Pet Inactivated Vaccine Product Portfolios and Specifications
13.7.3 Merck Animal Health Pet Inactivated Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
13.7.4 Merck Animal Health Main Business Overview
13.7.5 Merck Animal Health Latest Developments
13.8 Merial (Sanofi)
13.8.1 Merial (Sanofi) Company Information
13.8.2 Merial (Sanofi) Pet Inactivated Vaccine Product Portfolios and Specifications
13.8.3 Merial (Sanofi) Pet Inactivated Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
13.8.4 Merial (Sanofi) Main Business Overview
13.8.5 Merial (Sanofi) Latest Developments
13.9 Virbac
13.9.1 Virbac Company Information
13.9.2 Virbac Pet Inactivated Vaccine Product Portfolios and Specifications
13.9.3 Virbac Pet Inactivated Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
13.9.4 Virbac Main Business Overview
13.9.5 Virbac Latest Developments
13.10 Pfizer
13.10.1 Pfizer Company Information
13.10.2 Pfizer Pet Inactivated Vaccine Product Portfolios and Specifications
13.10.3 Pfizer Pet Inactivated Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
13.10.4 Pfizer Main Business Overview
13.10.5 Pfizer Latest Developments
14 Research Findings and Conclusion

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.

91制片厂